NCT03311295 (MAVERIC US) is a NA clinical trial of ARTO System in Mitral Valve Insufficiency, sponsored by Mvrx, Inc..

Who is sponsoring NCT03311295?

NCT03311295 is sponsored by Mvrx, Inc..

What drugs are being tested in NCT03311295?

Interventions in NCT03311295: ARTO System.

What condition does NCT03311295 study?

NCT03311295 studies Mitral Valve Insufficiency.

Is NCT03311295 still recruiting?

NCT03311295 is currently terminated. Last updated 28 April 2021.

Last reviewed 2021-04-28 · How we verify

NCT03311295: MAVERIC US

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial) - United States

Terminated NA Last updated 28 April 2021

What this trial tests

NA trial testing ARTO System in Mitral Valve Insufficiency in 1 participant. Terminated before completion.

Timeline

3 April 2018

Primary endpoint
26 April 2021

26 April 2021

Quick facts

Lead sponsor	Mvrx, Inc.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	3 April 2018
Primary completion	26 April 2021
Estimated completion	26 April 2021
Sites	1 location across United States

Drugs / interventions tested

ARTO System

Conditions studied

Mitral Valve Insufficiency — all drugs for Mitral Valve Insufficiency →

Sponsor

Mvrx, Inc.

Who can join

Adults 21 to 85, any sex, with Mitral Valve Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to evaluate the safety and feasibility of the ARTO System in patients with mitral valve regurgitation (MR) associated with congestive heart failure (CHF).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Mitral Interventions in Heart Failure.
Lander MM, Brener MI, Goel K, Tang PC, et al · · 2023 · cited 11× · PMID 37611988 · DOI 10.1016/j.jchf.2023.07.016
Emerging Technologies for Percutaneous Mitral Valve Repair.
Mangieri A, Laricchia A, Giannini F, Gallo F, et al · · 2019 · cited 11× · PMID 31781576 · DOI 10.3389/fcvm.2019.00161
Mortality and Clinical Predictors After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis.
Shi W, Zhang W, Zhang D, Ye G, et al · · 2022 · cited 4× · PMID 35859589 · DOI 10.3389/fcvm.2022.918712

Verify or expand the search:

Other recruiting trials for Mitral Valve Insufficiency

Currently open trials in the same condition.

NCT06757049 — Clinical Outcomes of Edwards Lifesciences MITRIS RESLILA Mitral Valve in the Asian Population · recruiting
NCT06235385 — European Association of Cardiovascular Imaging Multiple and Mixed Valvular Disease Study · recruiting
NCT05927441 — DragonFly EU Pivotal Study · NA · recruiting
NCT04343313 — The Half Moon Transcatheter Mitral Valve Repair (TMVr) Pilot Study · NA · recruiting
NCT04153292 — The ENCIRCLE Trial · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03311295 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mvrx, Inc.
Last refreshed: 28 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03311295.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing